H&E · Breast 2024 · section 1
- What the report says
- Invasive carcinoma of no special type with neuroendocrine differentiation, grade II (tubule formation 3, nuclear pleomorphism 2, mitotic activity 2). Ductal carcinoma in situ, micropapillary and cribriform pattern, nuclear atypia grade 2, no comedonecrosis (20% of the neoplasm).Source: Pathology report of the breast biopsy, January 2024Checked against the original report
- Sample
- Breast · diagnostic biopsy (2024) · section 1
- Laboratory
- Pathology department of the diagnosing hospital (Murcia)
- Date
- Report of January 2024
- Scanner
- Roche VENTANA DP 200 · 40× · 0.25 µm/px
About the samples
32 scanned slides from three of Miriam’s samples: the breast biopsy from her diagnosis (2024), the 2026 review of that same block and the 2026 liver biopsy. They open like a microscope, with zoom down to the cell and a micron ruler set to each scanner.
- Breast · diagnostic biopsy (2024)
- Roche VENTANA DP 200 · 40× · 0.25 µm/px
- Breast · review of the same block (2026)
- Grundium Ocus40 (inferido del formato) · 40× · 0.25055 µm/px. 2026 review of the same breast block (its report says so). Miriam confirms these scans are that review’s slides.
- Liver · 2026 biopsy
- Hamamatsu C13220 · 20× · 0.45886 µm/px
The neuroendocrine markers are chromogranin, synaptophysin, INSM1 and CD56.
If you want the full-resolution files, ask me through “Request the files”. Licensed under CC BY 4.0. SHA-256 checksums